NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Adma Biologics, Inc. ADMA
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$510.2M
▲ 19.6% vs FY2024
EPS · FY25
$0.60
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
35.6%
Net margin · FY25
28.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 510.2M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
29 cents of every revenue dollar became profit this year.
Per share
USD 0.60
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
35.6%
Return on equity, FY2025
ROE
Operating margin37.5%
Net margin28.8%
Return on assets26.4%
Each USD of equity produced 36 cents of profit this year.
Returned to shareholders
USD 29.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 29.0M
Share of profit19.7%
Consecutive raises—
USD 29.0M in buybacks — 20% of the year's profit went back to shareholders.
Growth
+64.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+49.0%
+64.6%
+53.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.24B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 624.2M
total assets, end of FY2025
Total assetsUSD 624.2M
EquityUSD 477.3M
CashUSD 87.6M
Gross debtUSD 72.1M
Net debtUSD -15.5M
Current ratio6.71×
The company holds more cash than debt.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.5
0.4
0.3
0.2
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.2
0.1
0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.2
0.1
0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
·
Net income $B
0.1
0.2
−0.0
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.60
0.81
−0.13
−0.33
−0.51
−0.88
−0.89
−1.45
−1.91
−1.61
−1.73
−1.81
−2.38
−1.39
−16.72
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
35.6
81.6
−19.7
−45.0
−62.5
−132.4
−210.1
−218.8
−243.9
·
−526.2
−121.9
−100.2
−148.9
−1530.1
Shares out B
0.24
0.24
0.23
0.22
0.20
0.10
0.06
0.00
0.01
0.00
0.01
0.01
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
59 of 59
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed